The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
Open accessAbstract
Purpose: To address whether all medically fit patients with curatively resected stage II colon cancer should be offered adjuvant chemotherapy as part of routine clinical practice, to identify patients with poor prognosis characteristics, and to describe strategies for oncologists to use to discuss adjuvant chemotherapy in practice. Methods: An American Society of Clinical Oncology Panel, in collaboration with the Cancer Care Ontario Practice Guideline Initiative, reviewed pertinent information from the literature through May 2003. Results: A literature-based meta-analysis found no evidence of a statistically significant survival benefit of adjuvant chemotherapy for stage II patients. Recommendations: The routine use of adjuvant chemotherapy for medically fit patients with stage II colon cancer is not recommended. However, there are populations of patients with stage II disease that could be considered for adjuvant therapy, including patients with inadequately sampled nodes, T4 lesions, perforation, or poorly differentiated histology. Conclusion: Direct evidence from randomized controlled trials does not support the routine use of adjuvant chemotherapy for patients with stage II colon cancer. Patients and oncologists who accept the relative benefit in stage III disease as adequate indirect evidence of benefit for stage II disease are justified in considering the use of adjuvant chemotherapy, particularly for those patients with high-risk stage II disease. The ultimate clinical decision should be based on discussions with the patient about the nature of the evidence supporting treatment, the anticipated morbidity of treatment, the presence of high-risk prognostic features on individual prognosis, and patient preferences. Patients with stage II disease should be encouraged to participate in randomized trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
American Joint Committee on Cancer (2002) · Springer eBooks · doi:10.1007/978-1-4757-3656-4 · Cited by 6,379
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationAJCC Cancer Staging Manual. 6th ed
Greene, F., Page, D., Id, F., Fritz, J., Balch, C., & Haller, D. (2002) · Cited by 2,324
Self-citationLevamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002083220602 · Cited by 2,256
Self-citationRibic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Prognostic Factors in Prostate Cancer: College of American Pathologists Consensus Statement 1999
Bostwick, D. G., Grignon, D. J., Hammond, M. E. H., Amin, M. B., Cohen, M., Crawford, D., Gospadarowicz, M., Kaplan, R. S., Miller, D. S., Montironi, R., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0995-pfipc · Cited by 1,239
Prognostic Factors in Colorectal Cancer: College of American Pathologists Consensus Statement 1999
Compton, C. C., Fielding, L. P., Burgart, L. J., Conley, B., Cooper, H. S., Hamilton, S. R., Hammond, M. E. H., Henson, D. E., Hutter, R. V. P., Nagle, R. B., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0979-pficc · Cited by 1,230
Le Voyer, T. E., Sigurdson, E. R., Hanlon, A. L., Mayer, R. J., Macdonald, J. S., Catalano, P. J., & Haller, D. G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.062 · Cited by 1,149
Self-citationAdjuvant Therapy for Patients With Colon and Rectal Cancer
(1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450110090034 · Cited by 1,086
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
(1995) · The Lancet · doi:10.1016/s0140-6736(95)90696-7 · Cited by 1,066
Gill, S., Loprinzi, C. L., Sargent, D. J., Thomé, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.059 · Cited by 1,021
Self-citationA Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
Sargent, D. J., Goldberg, R. M., Jacobson, S. D., Macdonald, J. S., Labianca, R., Haller, D. G., Shepherd, L. E., Seitz, J. F., & Francini, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010957 · Cited by 986
Self-citationMoertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-5-199503010-00001 · Cited by 925
Self-citationLaurie, J. A., Moertel, C. G., Fleming, T. R., Wieand, H. S., Leigh, J. E., Rubin, J., McCormack, G. W., Gerstner, J. B., Krook, J. E., & Malliard, J. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1447 · Cited by 700
The Prognosis of T3N0 Colon Cancer Is Dependent on the Number of Lymph Nodes Examined
Swanson, R. S., Compton, C. C., Stewart, A. K., & Bland, K. I. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.03.058 · Cited by 622
Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer
(1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1356 · Cited by 444
Rothenberg, M. L., Meropol, N. J., Poplin, E. A., Van Cutsem, E., & Wadler, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3801 · Cited by 425
Self-citationO'Connell, M. J., Laurie, J. A., Kahn, M., Fitzgibbons, R. J., Erlichman, C., Shepherd, L., Moertel, C. G., Kocha, W. I., Pazdur, R., Wieand, H. S., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.295 · Cited by 417
Self-citationColorectal Carcinoma: Diagnostic, Prognostic, and Molecular Features
Compton, C. C. (2003) · Modern Pathology · doi:10.1097/01.mp.0000062859.46942.93 · Cited by 403
Postoperative Adjuvant Chemotherapy or BCG for Colon Cancer: Results From NSABP Protocol C-011
Wolmark, N., Fisher, B., Rockette, H., Redmond, C., Wickerham, D. L., Fisher, E. R., Jones, J., Glass, A., Lerner, H., Lawrence, W., et al. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.1.30 · Cited by 400
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., & Glick, J. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2936 · Cited by 369
Self-citationFigueredo, A., Charette, M. L., Maroun, J., Brouwers, M. C., & Zuraw, L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.087 · Cited by 348
Self-citationSurvey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.
Ravdin, P. M., Siminoff, I. A., & Harvey, J. A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.515 · Cited by 262
Adjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon Cancer
Schrag, D., Rifas-Shiman, S., Saltz, L., Bach, P. B., & Begg, C. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.084 · Cited by 249
Self-citationGreene, F. L., Stewart, A. K., & Norton, H. J. (2002) · Annals of Surgery · doi:10.1097/00000658-200210000-00003 · Cited by 230
Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III
on behalf of the NACCP group*, Taal, B. G., Van Tinteren, H., & Zoetmulder, F. A. N. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2117 · Cited by 218
Wolmark, N., Rockette, H., Wickerham, D. L., Fisher, B., Redmond, C., Fisher, E. R., Potvin, M., Davies, R. J., Jones, J., & Robidoux, A. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1466 · Cited by 211
FIELDING, L. P., Hittinger, R., Grace, R., et al. (1992) · The Lancet · doi:10.1016/0140-6736(92)91708-g · Cited by 134
Portal Vein Chemotherapy for Colorectal Cancer: a Meta-analysis of 4000 Patients in 10 Studies
Liver Infusion Meta-analysis Group (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.7.497 · Cited by 121
Should Dukes' B patients receive adjuvant therapy? A statistical perspective
Buyse, M. E., & Piedbois, P. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90247-7 · Cited by 109
Beart, R. W. (1990) · Archives of Surgery · doi:10.1001/archsurg.1990.01410190095015 · Cited by 108
Understanding the Utility of Adjuvant Systemic Therapy for Primary Breast Cancer
Loprinzi, C. L., & Thomé, S. D. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.972 · Cited by 95
Chao, C., Studts, J. L., Abell, T. D., Hadley, T. J., Roetzer, L. M., Dineen, S. P., Lorenz, D., YoussefAgha, A. H., & McMasters, K. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.025 · Cited by 88
Cited by
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
“• For patients who have Stage II colorectal cancer with a high risk of recurrence, the indications for adjuvant chemotherapy are considered after obtaining informed consent [51, 52] (CQ-14).”
BackgroundAnand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
QUASAR Collaborative Group (2007) · The Lancet · doi:10.1016/s0140-6736(07)61866-2 · Cited by 1,437
Metadata
- Authors
- Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J., McAllister, P., Van Cutsem, E., Brouwers, M., Charette, M., & Haller, D. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-08-15
- Volume
- 22
- Issue
- 16
- Pages
- 3408-3419
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2141768150
- Cited by
- 1,430
- References
- 36
- FWCI
- 22.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.